We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 23

Germany seeks stricter nanomaterial reporting rules under REACH

  • Shook Hardy & Bacon LLP
  • -
  • European Union, Germany
  • -
  • May 10 2013

German safety regulators have apparently sought a major nanotechnologyrelated revision of the European Union's Registration, Evaluation

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

German Supreme Court finally finds patent on embryonic stem cell technology valid under reasonable terms while the position of the EPO is still open

  • Prüfer & Partner GbR
  • -
  • European Union, Germany
  • -
  • February 1 2013

Following the preliminary ruling of the Court of Justice of the European Union (CJEU; case C-3410), the long awaited final decision of the German

AG opinion on medical devices qualification issues for e-health software products

  • CMS Cameron McKenna
  • -
  • European Union, Germany
  • -
  • May 21 2012

On 15 May 2012, the Advocate General published his Opinion in the European Court of Justice reference in Brain Products GmbH v BioSemi VOF and Others by the German Supreme Court (Bundesgerichtshof

Updates on international pricing issues for pharmaceutical and biologic products

  • Sidley Austin LLP
  • -
  • China, European Union, France, Germany, United Kingdom, USA
  • -
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies

Stem cells confirmed too potent to patent in EU

  • Shepherd & Wedderburn LLP
  • -
  • European Union, Germany
  • -
  • November 18 2011

On 10 March 2011, Advocate General Bot delivered his opinion in relation to Case C-3410, a reference to the Court of Justice of the European Union (CJEU) from the German Federal Court of Justice (Bundesgerichtshof) in Oliver Brüstle v Greenpeace eV

Court of Justice clarifies exclusion against patenting of embryonic stem cells

  • CMS Cameron McKenna
  • -
  • European Union, Germany
  • -
  • October 26 2011

Under Article 5 of EU Directive 9844EC the “Biotech Directive”, the human body, at the various stages of its formation and development, and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot constitute patentable inventions

Ban on embryonic stem cell patenting in Europe Court of Justice rules on meaning of "human embryo" in stem cells debate

  • Hogan Lovells
  • -
  • European Union, Germany
  • -
  • October 25 2011

The Court of Justice of the European Union (CJEU) handed down its long-awaited judgment in the Brüstle case on the patentability of stem cell inventions

Minus 3 months and 2 weeks

  • Norrbom Vinding
  • -
  • European Union, Germany
  • -
  • September 15 2011

The EU Advocate General says that supplementary protection certificates can be issued with a negative term

Pharmaceutical trademarks

  • Siebeke Lange Wilbert
  • -
  • European Union, Germany
  • -
  • August 23 2011

During the last two years, the German courts have decided a number of cases involving pharmaceuticals and medical devices

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy